Literature DB >> 34127193

CRISPR-Cas9 for treating hereditary diseases.

Indra Mani1.   

Abstract

This chapter analyzes to use of the genome editing tool to the treatment of various genetic diseases. The genome editing method could be used to change the DNA in cells or organisms to understand their physiological response. Therefore, a key objective is to present general information about the use of the genome editing tool in a pertinent way. An emerging genome editing technology like a clustered regularly short palindromic repeats (CRISPR) is an extensively expended in biological sciences. CRISPR and CRISPR-associated protein 9 (CRISPR-Cas9) technique is being utilized to edit any DNA mutations associated with hereditary diseases to study in cells (in vitro) and animals (in vivo). Interestingly, CRISPR-Cas9 could be used to the investigation of treatments of various human hereditary diseases such as hemophila, β-thalassemia, cystic fibrosis, Alzheimer's, Huntington's, Parkinson's, tyrosinemia, Duchnene muscular dystrophy, Tay-Sachs, and fragile X syndrome disorders. Furthermore, CRISPR-Cas9 could also be used in other diseases to the improvement of human health. Finally, this chapter discuss current progress to treatment for hereditary diseases using CRISPR-Cas9 technology and highlights associated challenges and future prospects.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; Cas-9; Genetic diseases; Genome editing; Mutations

Year:  2021        PMID: 34127193     DOI: 10.1016/bs.pmbts.2021.01.017

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  1 in total

Review 1.  Molecular genetics of β-thalassemia: A narrative review.

Authors:  Tang-Her Jaing; Tsung-Yen Chang; Shih-Hsiang Chen; Chen-Wei Lin; Yu-Chuan Wen; Chia-Chi Chiu
Journal:  Medicine (Baltimore)       Date:  2021-11-12       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.